Role of Protopine and Nuciferine in the management of nocturia, urgency and dysuria in pre- and post-menopausal women: a prospective pilot study.

Gynecologic and Obstetric Investigation

Plotti F. · Silvagni A. · Cundari G.B. · Ficarola F. · De Cicco Nardone C. · Guzzo F. · Fabris S. · Luvero D. · Angioli R. · Terranova C. · Montera R.

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Access via DeepDyve Unlimited fulltext viewing of this article Organize, annotate And mark up articles Printing And downloading restrictions apply

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details Abstract

Abstract Objectives: Nocturia was commonly treated with drugs burdened with high costs and numerous side effects; in fact, more than 70% of patients drop out of long-term treatment. Protopine and Nuciferine are two alkaloids that have different effects on the neurotransmitter receptors involved in the regulation mechanism of the onset of urinary stimuli. The aim of the study is to evaluate the efficacy in controlling primarily nocturia and secondarily urgency and dysuria after three months of treatment with combination therapy of protopine and nuciferine syrup. Design: This is a prospective cohort study in which all patients were diagnosed with overactive bladder syndrome (OAB) and the presence of symptoms: nocturia, urgency, and dysuria. 30 patients are administered 10 ml/die (16.6 mg of Nuciferine – 0.09 mg of Protopine) of syrup for 3 months. Patients are evaluated at baseline (T0) with the ICIQ questionnaire (International Consultation on Incontinence), VAS (Visual Analogue Scale) for the evaluation of dysuria, PPIUS (Patient Perception of Intensity of Urgency Scale) and at 3 months (T1) with the PGI-C Scale (Patients' Global Impression of Change), PPIUS, VAS and ICIQ. Participants: Women with diagnosis of OAB; presence of nocturia, urgency, and dysuria symptoms agreeing to undergo treatment and compiling informed consent; absence of contraindications to the use of active ingredients. Setting: Patients were recruited at (T0) during the visit to the Uro-Gynecology clinic of the University of 'Campus Bio-Medico' and visited again 3 months (T1) after the initiation of therapy. Methods: We explored survey data by descriptive statistics: in particular, continuous values (i.e., ICIQ) have been summarized by mean and standard deviation, discrete ordinal values (i.e., VAS, PPIUS, and bladder diary parameters at T0 and T1) by median, minimum, and maximum reported scores. Where we could assume normality in distribution, assessed by the Shapiro-Wilk test and the evaluation of the QQ plot, we compared the observation T0 and T1 with the paired Student's t test, otherwise we tested differences in distribution with the paired Mann–Whitney U test. Results: Thirty patients completed a three-month therapy. The ICIQ, VAS questionnaires for the assessment of dysuria, both, reported an improvement in dysuria at T1 (p

S. Karger AG, Basel

Article / Publication Details Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

留言 (0)

沒有登入
gif